Evidence method
Level · gp.fundamentals.debt_to_revenue
576.77% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIP · Sep 30, 2015
ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001144204-15-062504General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
3.85% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
51.25% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
14.87% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
68.80% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
83.68% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
42.31% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
4.08% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
5.61% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 582.46%
- Current
- 576.77%
- Delta
- -5.68%
- Previous
- 1.01%
- Current
- 3.85%
- Delta
- 2.83%
- Previous
- 6.18%
- Current
- 51.25%
- Delta
- 45.07%
- Previous
- 193.61%
- Current
- 14.87%
- Delta
- -178.74%
- Previous
- 65.08%
- Current
- 68.80%
- Delta
- 3.72%
- Previous
- 83.91%
- Current
- 83.68%
- Delta
- -0.23%
- Previous
- 43.11%
- Current
- 42.31%
- Delta
- -0.80%
- Previous
- 5.10%
- Current
- 4.08%
- Delta
- -1.02%
- Previous
- 5.27%
- Current
- 5.61%
- Delta
- 0.34%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIP Fundamental State →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ANIP CAPEX_INTENSITY_INCREASED →Transitioned To · ANIP CASH_GENERATION_INCREASED →Transitioned To · ANIP GROWTH_DECREASED →Transitioned To · ANIP INVENTORY_PRESSURE_INCREASED →Transitioned To · ANIP MARGIN_DECREASED →Transitioned To · ANIP PROFITABILITY_DECREASED →Transitioned To · ANIP R_AND_D_INTENSITY_DECREASED →Transitioned To · ANIP SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.